Niels Henrik Ingvar Hjøllund

Patient-Reported Outcome Measures Used in Routine Care Predict for Survival at Disease Progression in Patients With Advanced Lung Cancer

Publikation: Bidrag til tidsskrift/Konferencebidrag i tidsskrift /Bidrag til avisTidsskriftartikelForskningpeer review

Standard

Patient-Reported Outcome Measures Used in Routine Care Predict for Survival at Disease Progression in Patients With Advanced Lung Cancer. / Friis, Rasmus Blechingberg; Hjøllund, Niels Henrik; Pappot, Helle; Taarnhøj, Gry Assam; Vestergaard, Jesper Medom; Skuladottir, Halla.

I: Clinical Lung Cancer, Bind 22, Nr. 2, 03.2021, s. e169-e179.

Publikation: Bidrag til tidsskrift/Konferencebidrag i tidsskrift /Bidrag til avisTidsskriftartikelForskningpeer review

Harvard

APA

CBE

MLA

Vancouver

Author

Bibtex

@article{d191cd52a6e34f1cbe896278b659751a,
title = "Patient-Reported Outcome Measures Used in Routine Care Predict for Survival at Disease Progression in Patients With Advanced Lung Cancer",
abstract = "Background: Patient-reported outcome (PRO) measures have been increasingly implemented in routine care to aid in clinical decision-making. However, the prognostic value of PRO measures as a tool for decision making is not easily interpreted by clinicians. Our aims were to explore the prognostic value of PRO measures at disease progression and the changes in PRO measures between treatment start (baseline) and disease progression. Patients and Methods: Since 2014, patients with lung cancer have completed an electronic version of the European Organization for Research and Treatment of Cancer Quality of Life Questionnaires C30 and LC-13 before every outpatient visit at the Department of Oncology, Hospital Unit West, Jutland, Denmark. The patients{\textquoteright} responses were used in routine care. Patients receiving palliative antineoplastic treatment were eligible for analysis if the questionnaire had been completed at the initiation of first-line treatment and at disease progression. The prognostic value of the scores was evaluated using a Cox proportional hazard model. A P value < .01 was considered statistically significant. Results: A total of 94 screened patients were included. At disease progression, survival could be predicted from the absolute score of the global health scale, 3 functional scales (physical, role, emotional), and 7 symptom scales (fatigue, pain, dyspnea, hemoptysis, lung cancer dyspnea, chest pain). In addition, changes in hemoptysis, dysphagia, dyspnea, and chest pain predicted for survival at progression. Conclusion: PRO measures used in routine care can provide clinicians with relevant prognostic information about patients with lung cancer at disease progression. These results show the potential value of PRO measures when used in clinical decision-making. The patient-reported outcomes (PROs) used in routine care are not easily interpreted. We evaluated symptom development during first-line palliative treatment using electronic PROs from 94 patients with advanced lung cancer. We identified specific symptom scales that predict for survival at disease progression. These results can aid in the clinical interpretation of PROs used for decision-making.",
keywords = "EORTC QLQ-C30, EORTC QLQ-LC13, Health-related quality of life, Palliative care, Prognosis",
author = "Friis, {Rasmus Blechingberg} and Hj{\o}llund, {Niels Henrik} and Helle Pappot and Taarnh{\o}j, {Gry Assam} and Vestergaard, {Jesper Medom} and Halla Skuladottir",
note = "Copyright {\textcopyright} 2020 The Author(s). Published by Elsevier Inc. All rights reserved.",
year = "2021",
month = mar,
doi = "10.1016/j.cllc.2020.09.014",
language = "English",
volume = "22",
pages = "e169--e179",
journal = "Clinical Lung Cancer",
issn = "1525-7304",
publisher = "Elsevier Inc.",
number = "2",

}

RIS

TY - JOUR

T1 - Patient-Reported Outcome Measures Used in Routine Care Predict for Survival at Disease Progression in Patients With Advanced Lung Cancer

AU - Friis, Rasmus Blechingberg

AU - Hjøllund, Niels Henrik

AU - Pappot, Helle

AU - Taarnhøj, Gry Assam

AU - Vestergaard, Jesper Medom

AU - Skuladottir, Halla

N1 - Copyright © 2020 The Author(s). Published by Elsevier Inc. All rights reserved.

PY - 2021/3

Y1 - 2021/3

N2 - Background: Patient-reported outcome (PRO) measures have been increasingly implemented in routine care to aid in clinical decision-making. However, the prognostic value of PRO measures as a tool for decision making is not easily interpreted by clinicians. Our aims were to explore the prognostic value of PRO measures at disease progression and the changes in PRO measures between treatment start (baseline) and disease progression. Patients and Methods: Since 2014, patients with lung cancer have completed an electronic version of the European Organization for Research and Treatment of Cancer Quality of Life Questionnaires C30 and LC-13 before every outpatient visit at the Department of Oncology, Hospital Unit West, Jutland, Denmark. The patients’ responses were used in routine care. Patients receiving palliative antineoplastic treatment were eligible for analysis if the questionnaire had been completed at the initiation of first-line treatment and at disease progression. The prognostic value of the scores was evaluated using a Cox proportional hazard model. A P value < .01 was considered statistically significant. Results: A total of 94 screened patients were included. At disease progression, survival could be predicted from the absolute score of the global health scale, 3 functional scales (physical, role, emotional), and 7 symptom scales (fatigue, pain, dyspnea, hemoptysis, lung cancer dyspnea, chest pain). In addition, changes in hemoptysis, dysphagia, dyspnea, and chest pain predicted for survival at progression. Conclusion: PRO measures used in routine care can provide clinicians with relevant prognostic information about patients with lung cancer at disease progression. These results show the potential value of PRO measures when used in clinical decision-making. The patient-reported outcomes (PROs) used in routine care are not easily interpreted. We evaluated symptom development during first-line palliative treatment using electronic PROs from 94 patients with advanced lung cancer. We identified specific symptom scales that predict for survival at disease progression. These results can aid in the clinical interpretation of PROs used for decision-making.

AB - Background: Patient-reported outcome (PRO) measures have been increasingly implemented in routine care to aid in clinical decision-making. However, the prognostic value of PRO measures as a tool for decision making is not easily interpreted by clinicians. Our aims were to explore the prognostic value of PRO measures at disease progression and the changes in PRO measures between treatment start (baseline) and disease progression. Patients and Methods: Since 2014, patients with lung cancer have completed an electronic version of the European Organization for Research and Treatment of Cancer Quality of Life Questionnaires C30 and LC-13 before every outpatient visit at the Department of Oncology, Hospital Unit West, Jutland, Denmark. The patients’ responses were used in routine care. Patients receiving palliative antineoplastic treatment were eligible for analysis if the questionnaire had been completed at the initiation of first-line treatment and at disease progression. The prognostic value of the scores was evaluated using a Cox proportional hazard model. A P value < .01 was considered statistically significant. Results: A total of 94 screened patients were included. At disease progression, survival could be predicted from the absolute score of the global health scale, 3 functional scales (physical, role, emotional), and 7 symptom scales (fatigue, pain, dyspnea, hemoptysis, lung cancer dyspnea, chest pain). In addition, changes in hemoptysis, dysphagia, dyspnea, and chest pain predicted for survival at progression. Conclusion: PRO measures used in routine care can provide clinicians with relevant prognostic information about patients with lung cancer at disease progression. These results show the potential value of PRO measures when used in clinical decision-making. The patient-reported outcomes (PROs) used in routine care are not easily interpreted. We evaluated symptom development during first-line palliative treatment using electronic PROs from 94 patients with advanced lung cancer. We identified specific symptom scales that predict for survival at disease progression. These results can aid in the clinical interpretation of PROs used for decision-making.

KW - EORTC QLQ-C30

KW - EORTC QLQ-LC13, Health-related quality of life

KW - Palliative care

KW - Prognosis

UR - http://www.scopus.com/inward/record.url?scp=85095603297&partnerID=8YFLogxK

U2 - 10.1016/j.cllc.2020.09.014

DO - 10.1016/j.cllc.2020.09.014

M3 - Journal article

C2 - 33160899

AN - SCOPUS:85095603297

VL - 22

SP - e169-e179

JO - Clinical Lung Cancer

JF - Clinical Lung Cancer

SN - 1525-7304

IS - 2

ER -